The BRAF-inhibitor PLX4720 inhibits CXCL8 secretion in BRAFV600E mutated and normal thyroid cells: a further anti-cancer effect of BRAF-inhibitors

CXCL8 is a chemokine secreted by normal and thyroid cancer cells with proven tumor-promoting effects. The presence of BRAFV600E mutation is associated with a more aggressive clinical behavior and increased ability to secrete CXCL8 by papillary-thyroid-cancer cells. Aim of this study was to test the...

Descripción completa

Detalles Bibliográficos
Autores principales: Coperchini, Francesca, Croce, Laura, Denegri, Marco, Awwad, Oriana, Ngnitejeu, Samuel Tata, Muzza, Marina, Capelli, Valentina, Latrofa, Francesco, Persani, Luca, Chiovato, Luca, Rotondi, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416278/
https://www.ncbi.nlm.nih.gov/pubmed/30867499
http://dx.doi.org/10.1038/s41598-019-40818-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416278/
https://www.ncbi.nlm.nih.gov/pubmed/30867499
http://dx.doi.org/10.1038/s41598-019-40818-w

Ejemplares similares